echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Japan approves Daiichi Sankyo's third-generation oncolytic HSV 1 for the treatment of malignant glioma

    Japan approves Daiichi Sankyo's third-generation oncolytic HSV 1 for the treatment of malignant glioma

    • Last Update: 2021-06-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recent popular reports from Yimaike ★ Invitation to the event2021 Oncolytic Virus Drug Development Forum is about to open in Shanghai ★ The financing has reached hundreds of millions in half a year, and the oncolytic virus has entered the fast laneYimai New Observation Click on the picture and register now June 16, 2021 /MedClub News/--Recently, Daiichi Sankyo Company Limited announced that its oncolytic virus product Delytact (teserpaturev/G47∆) has received conditional approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) , For the treatment of malignant glioma, this makes Delytact the fourth oncolytic virus product approved worldwide, and the first oncolytic virus product approved for the treatment of malignant glioma worldwide
    .

    G47∆ was invented by Dr.
    Tomoki Todo of the University of Tokyo.
    It is the third-generation oncolytic herpes simplex virus type 1 (HSV 1) and the first third-generation oncolytic HSV 1 tested in humans
    .

    G47∆ has a triple mutation, which is to add another deletion mutation (knockout α47) on the basis of the second generation HSV-1 G207, which enhances the virus's selective replication and anti-tumor effect in tumor cells, while maintaining the safety of G207
    .

    G47∆ has been shown to be effective in all evaluated solid tumor models, including glioma, breast cancer, prostate cancer, schwannoma, nasopharyngeal carcinoma, hepatocellular carcinoma, colorectal cancer, malignant peripheral schwannoma and thyroid In addition, studies have found that G47∆ can effectively eliminate cancer stem cells derived from human glioblastoma
    .

    G47∆ was awarded the title of orphan drug by MHLW of Japan in 2017 and the title of SAKIGAKE in 2016 for the treatment of patients with malignant glioma
    .

    Recommended reading: Is it about to usher in the third generation of oncolytic virus? Daiichi Sankyo submitted a marketing application for oncolytic herpes simplex virus to JapanYimai Meng revealed that oncolytic virus can selectively infect tumor cells, replicate in a large amount and eventually lyse tumor cells, and release tumor antigens in large quantities at the same time, improving Tumor microenvironment
    .

    In addition, in recent years, tumor immunotherapy has gradually been tilted towards combination therapy, and clinical evidence shows that oncolytic viruses can enhance tumor response rate to immune regulatory checkpoint inhibitors, CAR-T cells and other immunotherapy methods, which is a combination therapy strategy The ideal object in
    .

    Recommended reading: Tumor immune combination therapy is the mainstream research direction in the future.
    Will oncolytic virus + CAR-T/NK cell therapy be the killer of solid tumors? Yimi’s new observation has made oncolytic viruses once again a popular direction in tumor immunity research, but strictly speaking, only one product that has been marketed and approved is Amgen’s T-vec (Imlygic) approved by the FDA in 2015.
    It is the first oncolytic virus treatment drug approved by the FDA for the local treatment of patients with melanoma
    .

    In 2016, they were approved for listing in Europe and Canada
    .

    The domestic research and development strength in the field of oncolytic viruses cannot be underestimated
    .

    In 2003 and 2005, CFDA approved Sibiono's Jinzaosheng and Sanwei Biotechnology's Encore (H101) to be marketed
    .

    The clinical efficacy of the two products on the market in the early morning has not been recognized internationally, but with the improvement of the domestic clinical trial system and approval policy standards, it is believed that the strength of domestic oncolytic viruses will gradually gain international recognition
    .

    In addition to several oncolytic virus products already on the market, there are also numerous oncolytic virus products under development worldwide
    .

    Through the retrieval of the clinical trial database, there are currently more than 100 clinical research projects on oncolytic viruses worldwide
    .

    The projects that have not yet been put into the database and are undergoing preclinical research far exceed this number
    .

    In order to promote more and more oncolytic viruses to the clinic, and to promote oncolytic virus drugs to benefit more patients as soon as possible, Yimike, Innomicro, and Heyuan Bio will hold the 2021 lysis in Shanghai on August 20-21, 2021.
    Oncovirus Drug Development Forum, this forum takes the process optimization and large-scale production of oncolytic virus drugs as the entry point to discuss the key results of many clinical breakthroughs.
    We look forward to interacting with colleagues on site
    .

    Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
    The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
    More than 5% of users of investment institutions
    .

    In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.